In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Ex Input:
SECTION 1. SHORT TITLE.

This Act may be cited as the ''Regulatory Transparency, Patient
Access, and Effective Drug Enforcement Act of 2014''.

SEC. 2. SCHEDULING OF SUBSTANCES INCLUDED IN NEW FDA-APPROVED DRUGS.

Section 201 of the Controlled Substances Act (21 U.S.C. 811) is
amended by inserting after subsection (h) the following:
''(i) Within 45 days of receiving a recommendation from the
Secretary to add a drug or substance that has never been marketed in
the United States to a schedule under this title, the Attorney General
shall, without regard to the findings required by subsection (a) of
this section or section 202(b), issue an interim final rule, under the
exception for good cause described in subparagraph (B) of section
553(b) of title 5, United States Code, placing the drug or substance
into the schedule recommended by the Secretary. The interim final rule
shall be made immediately effective under section 553(d)(3) of title 5,
United States Code.''.

SEC. 3. ENHANCING NEW DRUG DEVELOPMENT.

Section 302 of the Controlled Substances Act (21 U.S.C. 822) is
amended by inserting after subsection (g) the following:
''(h)(1) A person who submits an application for registration to
manufacture or distribute a controlled substance in accordance with
this section may indicate on the registration application that the
substance will be used only in connection with clinical trials of a
drug in accordance with section 505(i) of the Federal Food, Drug, and
Cosmetic Act.
''(2) When an application for registration to manufacture or
distribute a controlled substance includes an indication that the
controlled substance will be used only in connection with clinical
trials of a drug in accordance with section 505(i) of the Federal Food,
Drug, and Cosmetic Act, the Attorney General shall--
''(A) make a final decision on the application for
registration within 180 days; or
''(B) provide notice to the applicant in writing of--
''(i) the outstanding issues that must be resolved
in order to reach a final decision on the application;
and
''(ii) the estimated date on which a final decision
on the application will be made.''.

SEC. 4. REGISTRATION PROCESS UNDER CONTROLLED SUBSTANCES ACT.

(a) Definitions.--
(1) Factors as may be relevant to and consistent with the
public health and safety.--Section 303 of the Controlled
Substances Act (21 U.S.C. 823) is amended by adding at the end
the following:
''(i) In this section, the phrase 'factors as may be relevant to
and consistent with the public health and safety' means factors that
are relevant to and consistent with the findings contained in section
101.''.
(2) Imminent danger to the public health or safety.--
Section 304(d) of the Controlled Substances Act (21 U.S.C.
824(d)) is amended--
(A) by striking ''(d) The Attorney General'' and
inserting ''(d)(1) The Attorney General''; and
(B) by adding at the end the following:
''(2) In this subsection, the phrase 'imminent danger to the public
health or safety' means that, in the absence of an immediate suspension
order, controlled substances will continue to be distributed or
dispensed by a registrant who knows or should know through fulfilling
the obligations of the registrant under this Act, or has reason to
believe that--
''(A) the dispensing is outside the usual course of
professional practice;
''(B) the distribution or dispensing poses a present or
foreseeable risk of adverse health consequences or death due to
the abuse or misuse of the controlled substances; or
''(C) the controlled substances will continue to be
diverted outside of legitimate distribution channels.''.
(b) Opportunity To Submit Corrective Action Plan Prior to
Revocation or Suspension.--Subsection (c) of section 304 of the
Controlled Substances Act (21 U.S.C. 824) is amended--
(1) by striking the last two sentences;
(2) by striking ''(c) Before'' and inserting ''(c)(1)
Before''; and
(3) by adding at the end the following:
''(2) An order to show cause under paragraph (1) shall--
''(A) contain a statement of the basis for the denial,
revocation, or suspension, including specific citations to any
laws or regulations alleged to be violated by the applicant or
registrant;
''(B) direct the applicant or registrant to appear before
the Attorney General at a time and place stated in the order,
but not less than 30 days after the date of receipt of the
order; and
''(C) notify the applicant or registrant of the opportunity
to submit a corrective action plan on or before the date of
appearance.
''(3) Upon review of any corrective action plan submitted by an
applicant or registrant pursuant to paragraph (2), the Attorney General
shall determine whether denial, revocation or suspension proceedings
should be discontinued, or deferred for the purposes of modification,
amendment, or clarification to such plan.
''(4) Proceedings to deny, revoke, or suspend shall be conducted
pursuant to this section in accordance with subchapter II of chapter 5
of title 5, United States Code. Such proceedings shall be independent
of, and not in lieu of, criminal prosecutions or other proceedings
under this title or any other law of the United States.
''(5) The requirements of this subsection shall not apply to the
issuance of an immediate suspension order under subsection (d).''.

SEC. 5. REPORT TO CONGRESS ON EFFECTS OF LAW ENFORCEMENT ACTIVITIES ON
PATIENT ACCESS TO MEDICATIONS.

(a) In General.--Not later than 1 year after the date of enactment
of this Act, the Secretary of Health and Human Services, acting through
the Commissioner of Food and Drugs and the Director of the Centers for
Disease Control and Prevention, and in consultation with the
Administrator of the Drug Enforcement Administration and the Director
of National Drug Control Policy, shall submit a report to the
Committees on the Judiciary of the House of Representatives, the
Committee on Energy and Commerce of the House of Representatives, the
Committee on the Judiciary of the Senate, and the Committee on Health,
Education, Labor and Pensions of the Senate identifying--
(1) obstacles to legitimate patient access to controlled
substances;
(2) issues with diversion of controlled substances; and
(3) how collaboration between Federal, State, local, and
tribal law enforcement agencies and the pharmaceutical industry
can benefit patients and prevent diversion and abuse of
controlled substances.
(b) Consultation.--The report under subsection (a) shall
incorporate feedback and recommendations from the following:
(1) Patient groups.
(2) Pharmacies.
(3) Drug manufacturers.
(4) Common or contract carriers and warehousemen.
(5) Hospitals, physicians, and other health care providers.
(6) State attorneys general.
(7) Federal, State, local, and tribal law enforcement
agencies.
(8) Health insurance providers and entities that provide
pharmacy benefit management services on behalf of a health
insurance provider.
(9) Wholesale drug distributors.

Ex Output:
Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014 - Amends the Controlled Substances Act to direct the Attorney General, within 45 days of receiving a recommendation from the Secretary of Health and Human Services (HHS) to add a drug or substance that has never been marketed in the United States to a schedule of controlled substances, to issue an interim final rule under the exception for good cause, placing it into the schedule recommended, effective immediately. Allows a person who submits an application for registration to manufacture or distribute a controlled substance to indicate on the registration application that the substance will be used only in connection with clinical trials of a drug. Requires the Attorney General to: (1) make a final decision on such application within 180 days, or (2) provide written notice to the applicant of the outstanding issues that must be resolved to reach a final decision and the estimated date on which such decision will be made. Defines: (1) "factors as may be relevant to and consistent with the public health and safety," and (2) "imminent danger to the public health or safety." Requires an order to show cause as to why a registration should not be denied, revoked, or suspended to notify the registrant of the opportunity to submit a corrective action plan on or before the date of appearance before the Attorney General. Requires the Attorney General, upon review of any such plan, to determine whether denial, revocation, or suspension proceedings should be discontinued or deferred for purposes of modification or clarification of such plan. Makes these requirements inapplicable to the issuance of an immediate suspension order. Directs the Secretary, acting through the Commissioner of Food and Drugs (FDA) and the Director of the Centers for Disease Control and Prevention (CDC), to identify: (1) obstacles to legitimate patient access to controlled substances; (2) issues with diversion of controlled substances; and (3) how collaboration between federal, state, local, and tribal law enforcement agencies and the pharmaceutical industry can benefit patients and prevent diversion and abuse of controlled substances.

Ex Input:
SECTION 1. SHORT TITLE.

This Act may be cited as the ''DNA Sexual Assault Justice Act of
2002''.

SEC. 2. ASSESSMENT ON BACKLOG IN DNA ANALYSIS OF SAMPLES.

(a) Assessment.--
(1) In general.--The Attorney General shall survey each law
enforcement jurisdiction to assess the backlog of DNA testing
of rape kit samples and other sexual assault evidence.
(2) Determinations.--The Attorney General, acting through
the Director of the National Institute of Justice, shall carry
out an assessment of Federal, State, local, and tribal
territories law enforcement jurisdictions to determine the
amount of--
(A) evidence contained in rape kits that has not
been subjected to DNA testing and analysis; and
(B) evidence from sexual assault crimes that has
not been subjected to DNA testing and analysis.
(b) Report.--
(1) In general.--Not later than 1 year after the date of
enactment of this Act, the Attorney General shall submit to
Congress a report on the assessment carried out under
subsection (a).
(2) Contents.--The report submitted under paragraph (1)
shall include--
(A) the results of the assessment carried out under
subsection (a);
(B) the number of rape kit samples and other
evidence from sexual assault crimes that have not been
subjected to DNA testing and analysis; and
(C) a plan for carrying out additional assessments
and reports to continue until all law enforcement
jurisdictions report no backlog in crime scene DNA
testing and analysis.
(c) Authorization of Appropriations.--There is authorized to be
appropriated such sums as may be necessary to carry out this section.

SEC. 3. GRANTS FOR ANALYSIS OF DNA SAMPLES FROM RAPE KITS.

Section 2(a) of the DNA Analysis Backlog Elimination Act of 2000
(42 U.S.C. 14135(a)) is amended--
(1) in paragraph (2), by inserting ''including samples from
rape kits and nonsuspect cases'' after ''crime scenes''; and
(2) by adding at the end the following:
''(4) To ensure that DNA testing and analysis of samples
from rape kits and nonsuspect cases are carried out in a timely
manner.''.

SEC. 4. INCREASED GRANTS FOR DNA ANALYSIS.

Section 2(j) of the DNA Analysis Backlog Elimination Act of 2000
(42 U.S.C. 14135(j)) is amended--
(1) in paragraph (1)--
(A) in subparagraph (B), by striking ''and'' at the
end; and
(B) by striking subparagraph (C) and inserting the
following:
''(C) $25,000,000 for fiscal year 2003;
''(D) $25,000,000 for fiscal year 2004;
''(E) $25,000,000 for fiscal year 2005; and
''(F) $25,000,000 for fiscal year 2006.''; and
(2) in paragraph (2), by striking subparagraphs (C) and (D)
and inserting the following:
''(C) $100,000,000 for fiscal year 2003;
''(D) $100,000,000 for fiscal year 2004;
''(E) $50,000,000 for fiscal year 2005; and
''(F) $50,000,000 for fiscal year 2006.''.

SEC. 5. AUTHORITY OF LOCAL GOVERNMENTS TO APPLY FOR AND RECEIVE DNA
BACKLOG ELIMINATION GRANTS.

Section 2 of the DNA Analysis Backlog Elimination Act of 2000 (42
U.S.C. 14135) is amended--
(1) in subsection (a), by inserting ''or eligible units of
local government'' after ''eligible States'';
(2) in subsection (b)--
(A) in the matter preceding paragraph (1), by
inserting ''or unit of local government'' after
''State'' each place that term appears;
(B) in paragraph (1), by inserting ''or unit of
local government'' after ''State'';
(C) in paragraph (3), by inserting ''or unit of
local government'' after ''State'' the first time that
term appears;
(D) in paragraph (4)--
(i) by inserting ''or unit of local
government'' after ''State''; and
(ii) by striking ''and'' after the
semicolon;
(E) in paragraph (5)--
(i) by inserting ''or unit of local
government'' after ''State''; and
(ii) by striking the final period and
inserting ''; and''; and
(F) by adding at the end the following:
''(6) if the applicant is a unit of local government,
certify that the applicant participates in a State laboratory
system.'';
(3) in subsection (c), by inserting ''or unit of local
government'' after ''State'';
(4) in subsection (d)(2)(A), by inserting ''or units of
local government'' after ''States'';
(5) in subsection (e)--
(A) in paragraph (1), by inserting ''or local
government'' after ''State'' each place that term
appears; and
(B) in paragraph (2), by inserting ''or unit of
local government'' after ''State'';
(6) in subsection (f), by inserting ''or unit of local
government'' after ''State'';
(7) in subsection (g)--
(A) in paragraph (1), by inserting ''or unit of
local government'' after ''State''; and
(B) in paragraph (2), by inserting ''or units of
local government'' after ''States''; and
(8) in subsection (h), by inserting ''or unit of local
government'' after ''State'' each place that term appears.

SEC. 6. IMPROVING ELIGIBILITY CRITERIA FOR BACKLOG GRANTS.

Section 2 of the DNA Analysis Backlog Elimination Act of 2000 (42
U.S.C. 14135) is amended--
(1) in subsection (b)--
(A) in paragraph (5) (as amended by section 5), by
striking ''and'' at the end;
(B) in paragraph (6) (as added by section 5), by
striking the period at the end and inserting: '';
and''; and
(C) by adding at the end the following:
''(7) ensure that each laboratory performing DNA testing or
analysis satisfies the quality assurance protocols and
practices described in subsection (d)(2).''; and
(2) by adding at the end the following:
''(k) Priority.--In awarding grants under this section, the
Attorney General shall give priority to a State or unit of local
government that has a significant rape kit or nonsuspect case backlog
as compared to other applicants.''.

SEC. 7. AUTHORIZATION FOR GRANTS FOR IMPROVED RESPONSES TO AND
INVESTIGATION OF SEXUAL ASSAULT CASES.

(a) Authorization of Grants.--The Attorney General shall make
grants to eligible entities to--
(1) carry out sexual assault examiner training and
certification;
(2) develop sexual assault examiner programs;
(3) acquire or improve forensic equipment;
(4) train law enforcement personnel in the handling of
sexual assault cases and the collection and use of DNA samples
for use as forensic evidence; and
(5) train law enforcement personnel to recognize, detect,
report, and respond to drug-facilitated sexual assaults.
(b) Eligible Entity.--For purposes of this section, the term
''eligible entity'' means--
(1) a State;
(2) a unit of local government;
(3) a college, university, or other institute of higher
learning;
(4) sexual assault examination programs, including sexual
assault forensic examiner (SAFE) programs, sexual assault nurse
examiner (SANE) programs, and sexual assault response team
(SART) programs; and
(5) a State sexual assault coalition.
(c) Application.--To receive a grant under this section--
(1) the chief executive officer of a State, unit of local
government, or university that desires a grant under this
section shall submit to the Attorney General--
(A) an application in such form and containing such
information as the Attorney General may require;
(B) certification that the testing will be done in
a laboratory that complies with the quality assurance
and proficiency testing standards for collecting and
processing DNA samples issued by the Director of the
Federal Bureau of Investigation under section 210303 of
the DNA Identification Act of 1994 (42 U.S.C. 14131);
(C) notice that the applicant is aware of, and
utilizing, uniform protocols and standards issued by
the Department of Justice on the collection and
processing of DNA evidence at crime scenes; and
(D) if the applicant is a unit of local government,
certification that the applicant participates in a
State laboratory system; and
(2) an existing or proposed sexual assault examination
program shall submit to the Attorney General--
(A) an application in such form and containing such
information as the Attorney General may require;
(B) certification that the program complies with
the standards and recommended protocol developed by the
Attorney General pursuant to section 1405 of the
Victims of Trafficking and Violence Protection Act of
2000 (42 U.S.C. 3796gg note); and
(C) notice that the applicant is aware of, and
utilizing, uniform protocols and standards issued by
the Department of Justice on the collection and
processing of DNA evidence at crime scenes.
(d) Priority.--In awarding grants under this section, the Attorney
General shall give priority to proposed or existing sexual assault
examination programs that are serving, or will serve, populations
currently underserved by existing sexual assault examination programs.
(e) Restrictions on Use of Funds.--
(1) Supplemental funds.--Funds made available under this
section shall not be used to supplant State funds, but shall be
used to increase the amount of funds that would, in the absence
of Federal funds, be made available from State sources for the
purposes of this section.
(2) Administrative costs.--An eligible entity may not use
more than 3 percent of the funds it receives under this section
for administrative expenses.
(3) Nonexclusivity.--Nothing in this section shall be
construed to limit or restrict the ability of proposed or
existing sexual assault examination programs to apply for and
obtain Federal funding from any other agency or department or
any other Federal Grant program.
(f) Authorization of Appropriations.--There are authorized to be
appropriated to the Department of Justice $15,000,000 for each of
fiscal years 2003 through 2006 to carry out this section.

SEC. 8. AUTHORIZING JOHN DOE DNA INDICTMENTS.

(a) Limitations.--Section 3282 of title 18, United States Code, is
amended--
(1) by striking ''Except'' and inserting the following:
''(a) Limitation.--Except''; and
(2) by adding at the end the following:
''(b) DNA Profile Indictment.--
''(1) In general.--In any indictment found for an offense
under chapter 109A, if the identity of the accused is unknown,
it shall be sufficient to describe the accused as an individual
whose name is unknown, but who has a particular DNA profile.
''(2) Exception.--Any indictment described in paragraph
(1), which is found within 5 years after the offense under
chapter 109A shall have been committed, shall not be subject
to--
''(A) the limitations period described in
subsection (a); and
''(B) the provisions of chapter 208 until the
individual is arrested or served with a summons in
connection with the charges contained in the
indictment.
''(3) Definition.--For purposes of this subsection, the
term 'DNA profile' means a set of DNA identification
characteristics.''.
(b) Privacy Protection Standard.--Section 10(a) of the DNA Analysis
Backlog Elimination Act of 2000 (42 U.S.C. 14135e(a)) is amended by
inserting before the period at the end the following: ''or in section
3282(b) of title 18, United States Code.''.
(c) Rules of Criminal Procedure.--Rule 7 of the Federal Rules of
Criminal Procedure is amended in subdivision (c)(1) by adding at the
end the following: ''For purposes of an indictment referred to in
section 3282 of title 18, United States Code, if the identity of the
defendant is unknown, it shall be sufficient to describe the defendant,
in the indictment, as an individual whose name is unknown, but who has
a particular DNA profile, as defined in that section 3282.''.

SEC. 9. INCREASED GRANTS FOR COMBINED DNA INDEX (CODIS) SYSTEM.

Section 210306 of the DNA Identification Act of 1994 (42
U.S.C.14134) is amended--
(1) by striking ''There'' and inserting the following:
''(a) In General.--There''; and
(2) by adding at the end the following:
''(b) Increased Grants for CODIS.--There is authorized to be
appropriated to the Federal Bureau of Investigation to carry out a
redesign of the Combined DNA Index System (CODIS) $9,646,000 for fiscal
year 2003.''.

SEC. 10. INCREASED GRANTS FOR FEDERAL CONVICTED OFFENDER PROGRAM
(FCOP).

Section 3 of the DNA Analysis Backlog Elimination Act of 2000 (42
U.S.C. 14135a) is amended by adding at the end the following:
''(g) Authorization of Appropriations.--There is authorized to be
appropriated to the Federal Bureau of Investigation to carry out this
section $497,000 for fiscal year 2003.''.

Ex Output:
DNA Sexual Assault Justice Act of 2002 - Directs the Attorney General to: (1) survey each law enforcement jurisdiction to assess the backlog of DNA testing of rape kit samples and other sexual assault evidence; and (2) make grants to eligible entities to carry out sexual assault examiner training and certification, develop sexual assault examiner programs, acquire or improve forensic equipment, and train law enforcement personnel in the handling of sexual assault cases.Amends the DNA Analysis Backlog Elimination Act of 2000 to: (1) ensure that DNA testing and analysis of samples from rape kits and non-suspect cases are carried out in a timely manner; (2) reauthorize grants; (3) authorize local governments to apply for and receive grants; (4) direct the Attorney General to give priority in awarding grants to a State or local governmental unit that has a significant rape kit or non-suspect case backlog; (5) expand the scope of DNA samples subject to privacy protections; and (6) authorize appropriations to the Federal Bureau of Investigation (FBI) for the collection and use of DNA identification information from certain Federal offenders.Amends: (1) the Federal criminal code and the Federal Rules of Criminal Procedure to authorize "John Doe" DNA indictments for sexual abuse (allows describing a person as an unknown individual who has a particular DNA profile if the identity of the accused or defendant is unknown); and (2) the DNA Identification Act of 1994 to authorize appropriations to the FBI to carry out a redesign of the Combined DNA Index System.

Ex Input:
SECTION 1. SHORT TITLE.

This Act may be cited as the ''Tinnitus Research for Military
Health Improvement Act''.

SEC. 2. FINDINGS.

Congress makes the following findings:
(1) Tinnitus, or the perception of sound where no external
source of such sound exists, is the most prevalent disabling
condition that affects members of the Armed Forces, most
notably those members who have been exposed to blast injuries
during combat, or other high noise level situations.
(2) Tinnitus is the leading service-connected disability
for returning members of the Armed Forces and the prevalence of
tinnitus is continuing to increase at alarming rates.
(3) An otologic, or ear, injury such as tinnitus has been
shown to decrease performance and situational awareness during
combat, seriously compromising the ability of a member of the
Armed Forces to hear and execute commands properly, thereby
jeopardizing not only the affected member but other members as
well.
(4) While certain types of sensory impairment in combat or
other military activities may be readily apparent, otologic
injuries such as tinnitus may not be easily noticeable, which
necessitates the need for more rigorous screening for tinnitus
before and after deployment, and for additional research to
distinguish tinnitus from other forms of brain injury incurred
during combat.
(5) Medical evidence to date suggests a demonstrated link
between tinnitus and post-traumatic stress disorder and
traumatic brain injury, such that improved understanding of
treatment of tinnitus may also directly advance research
efforts to address post-traumatic stress disorder and traumatic
brain injury.
(6) Improving the treatment and prevention of tinnitus will
benefit all members of the Armed Forces who are increasingly at
risk of injury from high-decibel equipment or explosive
devices.

SEC. 3. CENTER OF EXCELLENCE FOR THE STUDY OF TINNITUS.

(a) Establishment.--
(1) In general.--The Secretary of Defense shall establish
one or more Centers of Excellence (in this section referred to
as a ''center'') for the study of tinnitus.
(2) Location.--The Secretary shall establish a center at a
military installation in the United States where members of the
Armed Forces perform activities involving high rates of sound,
including artillery instruction and other basic combat training
related activities.
(b) Responsibilities.--A center shall have the responsibilities as
follows:
(1) To study and enhance existing treatment modalities for
members of the Armed Forces with tinnitus, including diagnosed
cases of recurrent, chronic, or severe tinnitus.
(2) To conduct basic and clinical research to prevent,
treat, and cure tinnitus, including studies on the neurological
changes in the brain associated with tinnitus.
(3) To coordinate research activities with the Defense
Centers of Excellence for Psychological Health and Traumatic
Brain Injury in order to establish a tinnitus data registry for
members of the Armed Forces affected with tinnitus and other
neurological conditions that will enhance scientific progress
toward improvements in treatment for tinnitus and associated
neurological combat related conditions.
(c) Reports.--Not later than one year after the date of the
enactment of this Act, and annually thereafter, the Secretary of
Defense shall submit to Congress a report on the activities of the
center.
(d) Authorization of Appropriations.--There is authorized to be
appropriated to carry out this section $7,000,000 for each of fiscal
years 2011 through 2016.

SEC. 4. AURAL SCREENINGS FOR MEMBERS OF THE ARMED FORCES.

(a) In General.--Paragraph (2) of section 1074f(b) of title 10,
United States Code, is amended by adding at the end the following new
subparagraph:
''(D) An aural screening, including an assessment of
tinnitus.''.
(b) Effective Date.--Section 1074f(b)(2) of title 10, United States
Code, as added by subsection (a) of this section, shall apply to
members of the Armed Forces who are deployed or return from deployment
on or after the date that is 30 days after the date of the enactment of
this Act.

SEC. 5. GRANT PROGRAM TO ENCOURAGE TINNITUS RESEARCH.

(a) In General.--Subject to the availability of appropriations
provided for such purpose, the Secretary of Defense shall establish a
program to award grants to institutions to assist such institutions in
conducting research on recurrent, chronic, or severe tinnitus and
peripheral neurological conditions, including research related to
neurology, pharmacology, audiology, otolaryngology, and other
disciplines that the Secretary determines appropriate according to
newly discovered evidence-based findings.
(b) Eligibility.--
(1) Teaching program.--An institution eligible to receive a
grant under this section is--
(A) a hospital with a teaching program described in
section 1861(b)(6) of the Social Security Act (42
U.S.C. 1395x); or
(B) an educational institution with demonstrated
expertise in tinnitus research.
(2) Application.--To be eligible to receive a grant under
this section, an institution shall submit an application to the
Secretary of Defense at such time, in such manner, and
containing such information as the Secretary may require. The
Secretary shall ensure that such applications are peer-reviewed
by multidisciplinary tinnitus experts from both the public and
private sector.
(c) Grant Amount.--An institution awarded a grant under this
section may not receive more than $2,500,000 per fiscal year under this
section.
(d) Reports.--Not later than December 31 of each year a grant may
be awarded under this section, the Secretary of Defense shall submit to
Congress a report on the grant program, including a summary of the
research related to tinnitus conducted by each grant recipient.
(e) Authorization of Appropriations.--There is authorized to be
appropriated to carry out this section $10,000,000 for each of fiscal
years 2011 through 2016.

SEC. 6. IMPROVING AURAL PROTECTION FOR MEMBERS OF THE ARMED FORCES.

(a) In General.--The Secretary of Defense shall examine methods to
improve the aural protection for members of the Armed Forces in combat.
(b) Report.--Not later than one year after the date of the
enactment of this Act, the Secretary shall submit to Congress a report
on the methods to improve aural protection examined under subsection
(a).

SEC. 7. EXECUTIVE AGENT FOR TINNITUS.

(a) Executive Agent.--Not later than 90 days after the date of the
enactment of this Act, the Secretary of Defense shall designate a
senior official of the Department of Defense to act as the executive
agent for tinnitus.
(b) Roles, Responsibilities, and Authorities.--
(1) In general.--Not later than one year after the date of
the enactment of this Act, and in accordance with Directive
5101.1, the Secretary of Defense shall prescribe the roles,
responsibilities, and authorities of the executive agent
designated under subsection (a).
(2) Specification.--The roles and responsibilities of the
executive agent designated under subsection (a) shall include
coordinating common functions related to tinnitus among the
military departments.
(c) Support.--In accordance with Directive 5101.1, the Secretary of
Defense shall ensure that the military departments, Defense Agencies,
and other components of the Department of Defense provide the executive
agent designated under subsection (a) with the appropriate support and
resources needed to perform the roles, responsibilities, and
authorities of the executive agent.
(d) Definitions.--In this section:
(1) The term ''Directive 5101.1'' means Department of
Defense Directive 5101.1, or any successor directive relating
to the responsibilities of an executive agent of the Department
of Defense.
(2) The term ''executive agent'' has the meaning given the
term ''DoD Executive Agent'' in Directive 5101.1.

Ex Output:
Tinnitus Research for Military Health Improvement Act - Directs the Secretary of Defense (DOD) to establish one or more centers of excellence for the study of tinnitus. Requires such centers to be established at military installations where members of the Armed Forces perform activities involving high rates of sound, including artillery instruction. Outlines center activities, including researching and enhancing treatments for members with tinnitus.

Requires the inclusion, within a current medical tracking system for members deployed overseas, of an aural screening which shall include an assessment of tinnitus.

Directs the Secretary to establish a grant program to assist eligible institutions in conducting research on recurrent, chronic, or severe tinnitus and peripheral neurological conditions. Makes eligible for such grants: (1) a hospital with an approved teaching program as defined under the Social Security Act; or (2) an educational institution with demonstrated expertise in tinnitus research.

Requires the Secretary to designate a senior DOD official to act as the executive agent for tinnitus.